Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.K.’s CRT To Develop Lorus Cancer Drug

by Lisa M. Jarvis
December 3, 2012 | A version of this story appeared in Volume 90, Issue 49

Cancer Research Technology, the commercial arm of the nonprofit Cancer Research UK, will initiate a clinical trial for IL-17E, a Lorus Therapeutics cancer treatment. IL-17E is the third biologic that CRT has brought into its portfolio as part of a program that allows companies to keep the rights to drugs that the nonprofit evaluates. CRT will fund both preclinical and Phase I studies. If Lorus does not elect to continue developing IL-17E after seeing Phase I data, rights will be transferred to CRT.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.